chemie.pr-Bankkaufmann - News
Auf dieser Seite finden Sie Neuigkeiten zum Thema: Aktuelle SemBioSys Demonstrates Functionality of its Safflower Produced Apo AI(Milano) 05.06.2008
SemBioSys Demonstrates Functionality of its Safflower Produced Apo AI(Milano)
05.06.2008 13:40:04
SemBioSys, Genetics Inc: Calgary, Canada (ots/PRNewswire) - - Company Achieves Important Milestone in Development of Next Generation Cardiovascular Drug SemBioSys Genetics Inc. (TSX:SBS), a biotechnology company dedicated to developing a portfolio of therapeutic ...
Lesen Sie hier weiter... |
Drucken |
PDF
Ähnliche Artikel
- SemBioSys Submits IND for Safflower-Produced Insulin to U.S. FDA
- SemBioSys Eligible to Proceed With Phase I/II Plant-Produced Insulin Trial After Submission of IND
- Das Ospedale Niguarda Ca' Granda-Milano arbeitet zukünftig mit allerneuester Technologie zur Behandlung von Patienten mit Herzinsuffizienz
- Botaneco Receives Natural Ingredient Approval From ECOCERT(R) for Hydresia(TM) G2
- Biosensors DES Demonstrates Equivalent Safety and Efficacy to Industry Leading DES in First'Real World, All Comers' Clinical Study
- CRESTOR Demonstrates Dramatic CV Risk Reduction in a Large Statin Outcomes Study
- TMC278 Demonstrates Long-Term Efficacy and Tolerability in Treatment-Naïve Adults With HIV
- GRAZAX(R) Demonstrates Significant Reductions on Asthma Symptoms in Children
- Bimatoprost / Timolol Fixed Combination Therapy Demonstrates Significantly Better IOP Control Over 12 Hours Compared to Latanoprost / Timolol Combination
- Roche's R1626, First-in-Class Hepatitis C Polymerase Inhibitor, Demonstrates Impressive End-of-Treatment Response in Phase IIa Study
Presseportal: SemBioSys, Genetics Inc
SemBioSys Demonstrates Functionality of its Safflower Produced Apo AI(Milano) SemBioSys Confirms Commercially Viable Levels of Native APO AI in Safflower
ots.at: das APA-OTS-Portal für multimediale Presseaussendungen
SemBioSys Demonstrates Functionality of its Safflower Produced Apo AI(Milano) SemBioSys Confirms Commercially Viable Levels of Native APO AI in Safflower
Presseportal: SemBioSys, Genetics Inc - SemBioSys wählt ehemaligen ...
13:03 SemBioSys Demonstrates Functionality of its Safflower Produced Apo AI(Milano) 12:07 SemBioSys Initiates Toxicology Study for Safflower-Produced Insulin
SEMBIOSYS GENETICS INC Aktien | 000 | CA81661X1078 |
SemBioSys Demonstrates Functionality of its Safflower Produced Apo CNX Marketlink SemBioSys initiates toxicology study for safflower-produced insulin